GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and Accord BioPharma, Inc, the U.S. specialty division ofIntas Pharmaceuticals, Ltd.(&qu...
View DetailsGuangzhou, China --(BUSINESS WIRE)--Bio-Thera Solutions, a commercial-stage biopharmaceutical company developing apipeline of innovative therapies and a pipeline of biosimilars, today announcedthe company will present two posters at the 2022 San Anto...
Guangzhou, China --(BUSINESSWIRE)--Bio-Thera Solutions, Ltd. (688177.SH), a commercial-stage pharmaceuticalcompany, today announced that dosing has begun in a Phase III clinical studyfor BAT2306, a proposed biosimilar of Cosentyx® (secukinumab). The ...
Guangzhou, China --(BUSINESSWIRE)-- Bio-TheraSolutions, Ltd. (SH: 688177),a commercial-stage biopharmaceutical company, today announced that dosing hasbegun in a Phase I clinical study to compare the pharmacokinetics and safety ofBAT2606, a proposed ...
